RxDoctor Payments Data

Sundara Rameshwar Munagala Venkata, MD

Psychiatry · Cedar Rapids, IANPI 1225140809

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 26.2% of the total. Reporting peaked in 2019 at $756 and has fallen 98.1% since, to $14 in 2025.

$867in general payments, 2019–2025

Across 68 payments — averaging $12.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$227
  • AbbVie$179
  • Otsuka America Pharmaceutical, Inc.$163
  • Alkermes, Inc.$85
  • Sunovion Pharmaceuticals Inc.$44
  • Teva Pharmaceuticals USA, Inc.$38
  • plus $131 from 6 others

What the payments were for

  • Food & beverage$867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$867 in reported general payments places this provider in the 75th percentile of 245 psychiatry providers in Iowa.

See all psychiatry providers in Iowa

Medicare billing

Part B allowed, 2024
$75,742
Medicare patients
209
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl65$90,483
IngrezzaValbenazine Tosylate11$74,425
Invega SustennaPaliperidone Palmitate23$54,324
AustedoDeutetrabenazine12$32,116
Lurasidone Hcl132$27,813
Bupropion XlBupropion Hcl687$11,525
LexaproEscitalopram Oxalate16$10,630
Aripiprazole270$8,345
Duloxetine Hcl435$7,061
Trazodone Hcl699$6,649
Venlafaxine Hcl ErVenlafaxine Hcl272$6,211
Olanzapine279$5,873
Divalproex Sodium ErDivalproex Sodium113$5,555
Quetiapine Fumarate267$3,949
Hydroxyzine Pamoate207$3,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Lexapro$179$101,11381 claims
Neurocrine Biosciences, Inc.Ingrezza$25$74,42511 claims
Johnson & JohnsonInvega Sustenna$227$54,32423 claims
Teva Pharmaceuticals USA, Inc.Austedo$38$32,11612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 245 psychiatry providers in Iowa.

Other psychiatry in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →